OTHER CONDENSED CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Payables and Accruals [Abstract] |
|
| Schedule of Accrued Liabilities |
Accrued liabilities consisted of the following as of June 30, 2026 and December 31, 2025: | | | | | | | | | | | | | | | | (In thousands) | | JUNE 30,
2026 | | DECEMBER 31,
2025 | | Contract research organization and clinical trial costs | | $ | 5,190 | | | $ | 3,677 | | | Manufacturing activities | | 11,609 | | | 38,657 | | | Professional, legal and accounting fees | | 3,623 | | | 881 | | | Interest payable | | — | | | 3,110 | | | Accrued revenue adjustments | | 6,704 | | | 3,486 | | | Other | | 3,589 | | | 1,529 | | | | $ | 30,715 | | | $ | 51,340 | |
|
| Schedule of Accrued Compensation and Benefits |
Accrued compensation and benefits consisted of the following as of June 30, 2026 and December 31, 2025: | | | | | | | | | | | | | | | | (In thousands) | | JUNE 30,
2026 | | DECEMBER 31,
2025 | | Accrued bonuses | | $ | 5,937 | | | $ | 10,335 | | | Accrued vacation | | 2,189 | | | 2,581 | | | Accrued restructuring charges | | 178 | | | 17,032 | | | Accrued other | | 802 | | | 549 | | | | $ | 9,106 | | | $ | 30,497 | |
|
| Schedule of Cash and Cash Equivalents |
Cash, cash equivalents, and restricted cash included in the Company's condensed consolidated statement of cash flows were as follows: | | | | | | | | | | | | | | | | (In thousands) | | JUNE 30,
2026 | | JUNE 30,
2025 | | Cash and cash equivalents | | $ | 62,643 | | | $ | 77,734 | | | Restricted cash | | 1,888 | | | 1,870 | | | Total cash, cash equivalents, and restricted cash | | $ | 64,531 | | | $ | 79,604 | |
|
| Schedule of Restrictions on Cash and Cash Equivalents |
Cash, cash equivalents, and restricted cash included in the Company's condensed consolidated statement of cash flows were as follows: | | | | | | | | | | | | | | | | (In thousands) | | JUNE 30,
2026 | | JUNE 30,
2025 | | Cash and cash equivalents | | $ | 62,643 | | | $ | 77,734 | | | Restricted cash | | 1,888 | | | 1,870 | | | Total cash, cash equivalents, and restricted cash | | $ | 64,531 | | | $ | 79,604 | |
|